Taf4a HFD

Taf4a HFD is a therapeutic candidate consisting of the histone fold domain (HFD) of the TAF4A protein. It was developed by researchers at Cold Spring Harbor Laboratory as a targeted therapy for acute myeloid leukemia (AML). The mechanism involves acting as a dominant-negative decoy that binds to TAF12, a subunit of the TFIID co-activator complex. This binding prevents TAF12 from dimerizing with endogenous TAF4A and interacting with the transactivation domain (TAD) of the oncogenic transcription factor Myb (c-Myb). By disrupting the TAF12-Myb interaction, Taf4a HFD selectively inhibits the expression of Myb-dependent genes required for leukemia cell survival and progression, leading to tumor regression in preclinical models.

Other names

TAF4A histone fold domainTAF-4A histone fold domainTAF 4A histone fold domainTaf4a-HFDTaf-4a-HFDTaf 4a-HFD